摘要
We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor (EGF) receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar). Anti-tumor activity was assessed by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computer tomography (PET/CT) at baseline and then every 4 wk. The case illustrates that 18FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. 18FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.
We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor （EGF） receptor antibody （Cetuximab） plus recombinant human endostatin （Endostar）. Anti-tumor activity was assessed by ^18F-fluorodeoxyglucose （^18F-FDG） positron emission tomography/computer tomography （PET/CT） at baseline and then every 4 wk. The case illustrates that ^18FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. ^18FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.
关键词
肝转移
重组体
胃癌
治疗
Hepatic metastasis
Remnant gastriccancer
Cetuximab
Recombinant human endostatin
^18F-fluorodeoxyglucose
Positron emission tomography/computer tomography
